denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.
Program: Spotlight Sessions
Session: Emicizumab’s Impact on the Landscape of Hemophilia A Treatment: Two Artists Debate the View
Hematology Disease Topics & Pathways:
Hemophilia, Biological, antibodies, Diseases, Bleeding and Clotting, Therapies, Adverse Events, Clinically relevant
Session: Emicizumab’s Impact on the Landscape of Hemophilia A Treatment: Two Artists Debate the View
Hematology Disease Topics & Pathways:
Hemophilia, Biological, antibodies, Diseases, Bleeding and Clotting, Therapies, Adverse Events, Clinically relevant
Saturday, December 5, 2020, 11:55 AM-12:00 PM
Disclosures: Young: Genentech/Roche, Grifols, and Takeda: Research Funding; Bayer, CSL Behring, Freeline, UniQure: Consultancy; BioMarin, Freeline, Genentech/Roche, Grifols, Kedrion, Novo Nordisk, Sanofi Genzyme, Spark, Takeda, and UniQure: Honoraria.
See more of: Emicizumab’s Impact on the Landscape of Hemophilia A Treatment: Two Artists Debate the View
See more of: Spotlight Sessions
See more of: Spotlight Sessions
Previous Presentation
|
Next Presentation >>